12 Best Diagnostics Stocks to Invest In Right Now
According to a report by Mordor Intelligence, the clinical diagnostics market has a size of $88.79 billion as of 2025.
Charles River Laboratories International Inc. (CRL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impactive Capital Lauren Taylor Wolfe | 1,202,339 | $221,951,779 | +220% | 9.1% |
| 2. | Ariel Investments John W. Rogers | 1,067,327 | $197,028,565 | +19% | 2.1% |
| 3. | D1 Capital Partners Daniel Sundheim | 935,820 | $172,752,372 | 2.87% | |
| 4. | Eminence Capital Ricky Sandler | 627,472 | $115,831,331 | -38% | 1.77% |
| 5. | Southpoint Capital Advisors John Smith Clark | 600,000 | $110,760,000 | -11% | 2.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.01 | 6,075 | Officer, Director | 183,639 | 2025-02-20 | Filing | |
| $164.63 | 1,514 | Officer | 55,058 | 2025-02-20 | Filing | |
| $187.82 | 1,322 | Officer | 44,449 | 2023-11-20 | Filing | |
| $178.05 | 5,620 | Officer, Director | 202,643 | 2023-11-14 | Filing | |
| $198.79 | 1,000 | Director | 1,000 | 2023-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $162.50 | 4,400 | Officer | 20,013 | 2025-02-20 | Filing | |
| $216.50 | 1,000 | Director | 0 | 2024-11-07 | Filing | |
| $216.50 | 3,250 | Director | 12,386 | 2024-11-07 | Filing | |
| $215.75 | 3,371 | Director | 15,636 | 2024-11-07 | Filing | |
| $199.36 | 1,780 | Officer | 22,521 | 2024-08-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 96,526 | $14,529,093 | 0.21% | |
| 2. | 86,730 | $13,054,539 | 0.01% | |
| 3. | 48,742 | $7,336,613 | 0.27% | |
| 4. | 11,745 | $1,767,857 | 0.02% | |
| 5. | 7,476 | $1,125,288 | 0.11% |
News See All
Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings
Bell Asset Management, an investment management company, released its Q4 2024 “Bell Global Equities Fund” investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript February 19, 2025Charles River Laboratories International, Inc. beats earnings expectations.
10 AI News Updates on Wall Street's Radar
The rapid expansion of AI has started an unexpected growth in energy demand, which raises concerns about power availability, grid capacity, and sustainability.
RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL)
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.
What Makes Charles River Labs (CRL) an Investment Bet?
Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2024 Earnings Call Transcript November 6, 2024Charles River Laboratories International, Inc. beats earnings expectations.
Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL)
Brown Capital Management, an investment management company, released its “The Brown Capital Management Mid Company Fund” second quarter 2024 investor letter.
Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” second-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2024 Earnings Call Transcript August 7, 2024Charles River Laboratories International, Inc. beats earnings expectations.
Billionaire Hedge Funds
